Proof-of-concept studies in murine and canine models have shown the potential of gene therapy for RPE65-associated retinopathy, which has led to the initiation of human clinical gene-therapy trials [20,21,22,23,24]. This evidence concerns the gene RPE65 and retinal disorder.